Neuroinflammation represents a unifying pathological feature across all major neurodegenerative diseases, including [Alzheimer's Disease](/diseases/alzheimers-disease) (AD), [Parkinson's Disease](/diseases/parkinsons-disease) (PD), [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis) (ALS), [Frontotemporal Dementia](/diseases/frontotemporal-dementia) (FTD), and [Huntington's Disease](/diseases/huntingtons-disease) (HD). While each disease has distinct clinical manifestations and primary proteinopathies, chronic activation of the innate immune system in the central nervous system drives neuronal dysfunction and death across all five conditions [1]. [@schwabe2022]
This hub page synthesizes the common inflammatory pathways shared across these diseases while highlighting disease-specific mechanisms. Understanding these shared pathways is critical for developing therapeutic interventions that may benefit multiple neurodegenerative conditions [2]. [@gao2021]
Neuroinflammation represents a unifying pathological feature across all major neurodegenerative diseases, including [Alzheimer's Disease](/diseases/alzheimers-disease) (AD), [Parkinson's Disease](/diseases/parkinsons-disease) (PD), [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis) (ALS), [Frontotemporal Dementia](/diseases/frontotemporal-dementia) (FTD), and [Huntington's Disease](/diseases/huntingtons-disease) (HD). While each disease has distinct clinical manifestations and primary proteinopathies, chronic activation of the innate immune system in the central nervous system drives neuronal dysfunction and death across all five conditions [1]. [@schwabe2022]
This hub page synthesizes the common inflammatory pathways shared across these diseases while highlighting disease-specific mechanisms. Understanding these shared pathways is critical for developing therapeutic interventions that may benefit multiple neurodegenerative conditions [2]. [@gao2021]
The key cell types involved include [microglia](/cell-types/microglia), [astrocytes](/cell-types/astrocytes), and [oligodendrocytes](/cell-types/oligodendrocytes). Key pathways include the [NLRP3 inflammasome](/mechanisms/nlrp3-inflammasome), [TREM2 signaling](/proteins/trem2), [complement system](/mechanisms/complement-system-pathway), and [TLR signaling](/mechanisms/toll-like-receptor-signaling). Relevant proteins include [tau](/proteins/tau), [alpha-synuclein](/proteins/alpha-synuclein), [amyloid-beta](/proteins/amyloid-beta), [TDP-43](/proteins/tdp-43), and [SOD1](/proteins/sod1).
The concept of neuroinflammation has evolved significantly over the past decades. Initially viewed as a secondary response to neuronal injury, neuroinflammation is now recognized as a primary pathogenic mechanism that initiates and amplifies neurodegeneration [3]. The recognition that protein aggregates themselves activate inflammatory pathways has been particularly important in understanding disease mechanisms. [@boillee2006]
It is essential to distinguish between acute and chronic neuroinflammation: [@lopez2022]
Acute neuroinflammation: A protective response to injury or infection, characterized by transient microglial activation and controlled cytokine release. This response aids in tissue repair and pathogen clearance. [@crotti2021]
Chronic neuroinflammation: A persistent, maladaptive state where microglia and astrocytes remain activated, continuously releasing pro-inflammatory mediators. This chronic state drives progressive neuronal dysfunction and death. Chronic neuroinflammation is a hallmark of all neurodegenerative diseases. [@cheng2022]
Despite the heterogeneous nature of neurodegenerative diseases, several core inflammatory mechanisms are conserved [4]: [@shen2021]
Microglia are the resident immune cells of the brain and the primary drivers of neuroinflammation. Single-cell transcriptomic studies have identified multiple microglial states [5]: [@ransohoff2016]
Homeostatic Microglia: Survey the brain environment through continuous process movement, maintaining tissue homeostasis, synaptic pruning, and clearance of cellular debris. These cells express specific markers including P2RY12, CX3CR1, and TMEM119. [@aguzzi2013]
Disease-Associated Microglia (DAM): Upregulate genes including TREM2, APOE, CD68, involved in phagocytosis but also pro-inflammatory responses. DAM represent a transitional state from homeostatic to fully activated microglia. [@sedgewick2018]
Lipid-Accumulating Microglia (LAM): Specialized subset associated with lipid metabolism, particularly relevant in AD where these cells are found near amyloid plaques. [@hammond2019]
Proliferative-region-associated microglia (PAM): Found in neurogenic niches, these microglia support neural stem cell function but can become pathogenic. [@kerenshaul2017]
Microglia in specific diseases: [@zhou2016]
Astrocytes undergo reactive changes in neurodegeneration, a process called astrocytosis or reactive astrogliosis [6]: [@gomeznicola2015]
A1 Phenotype: Neurotoxic, upregulated in AD, PD, ALS; release complement components (C3, C4) that contribute to synaptic loss. A1 astrocytes are induced by microglial release of IL-1α, TNF, and C1q. [@calsolaro2016]
A2 Phenotype: Potentially protective, upregulated in ischemia and trauma; express neurotrophic factors and promote tissue repair.
Astrocytic Swelling: Contributes to water imbalance and excitotoxicity through dysregulation of astrocytic glutamate transporters.
Astrocyte dysfunction in disease:
Oligodendrocyte vulnerability and demyelination contribute to neuroinflammation and are increasingly recognized in neurodegenerative diseases [7]:
The role of peripheral immune cells in neuroinflammation has gained significant attention:
T cells: CD4+ and CD8+ T cells infiltrate the CNS in neurodegeneration. Regulatory T cells (Tregs) may be protective, while effector T cells contribute to pathology.
B cells: Autoantibodies and B cell infiltration have been reported in some neurodegenerative conditions.
Monocytes/Macrophages: Peripheral monocytes can infiltrate the brain and contribute to neuroinflammation.
The NF-κB pathway is a central regulator of neuroinflammation, activated by [8]:
Mitogen-activated protein kinase (MAPK) pathways contribute to neuroinflammation:
p38 MAPK: Activated by stress and cytokines, regulates production of pro-inflammatory mediators. p38 inhibitors have been tested in clinical trials.
JNK pathway: Involved in stress responses and inflammation-induced apoptosis.
The NLRP3 inflammasome is a key driver of neuroinflammation [9]:
Activation: Triggered by Aβ, α-synuclein, TDP-43, and mitochondrial DAMPs
Assembly: NLRP3 recruits ASC and pro-caspase-1, forming an active inflammasome complex
IL-1β maturation: Caspase-1 cleaves pro-IL-1β and pro-IL-18 to their active forms
Release: Inflammasome activation leads to gasdermin D-mediated pyroptosis and cytokine release
The cGAS-STING pathway senses cytosolic DNA and activates type I interferon responses [10]:
Activation: Mitochondrial DNA release, nuclear envelope rupture, and pathogens trigger cGAS activation
cGAMP production: cGAS produces cyclic GMP-AMP (cGAMP) second messenger
STING activation: cGAMP binds STING, leading to TBK1/IRF3 activation
Type I IFN response: IRF3-dependent transcription of interferon-stimulated genes
This pathway is increasingly recognized as important in neurodegeneration.
Neuroinflammation in AD involves several unique features [11]:
Amyloid-triggered inflammation: Aβ activates microglia through multiple receptors including TLRs, CD36, and TREM2. This activation leads to NF-κB and NLRP3 inflammasome activation.
Tau-mediated pathology: Pathological tau activates microglia through the NLRP3 inflammasome, creating a vicious cycle.
Complement activation: The complement system is heavily involved in AD neuroinflammation:
Neuroinflammation in PD has several distinctive characteristics [12]:
Substantia nigra vulnerability: The substantia nigra pars compacta shows particularly high levels of microglial activation in PD.
α-Synuclein as trigger: α-Synuclein aggregates activate microglia through multiple mechanisms:
ALS shows particularly prominent neuroinflammation [13]:
Microglial activation: Widespread microglial activation in motor cortex, spinal cord, and even preclinical regions.
TDP-43 pathology: TDP-43 aggregates in ALS activate the NLRP3 inflammasome.
Astrocyte toxicity: Non-neuronal cells in ALS release factors toxic to motor neurons.
SOD1 mutations: Mutant SOD1 in familial ALS triggers microglial activation and drives disease progression.
Therapeutic implications: Microglial modulation is a key therapeutic strategy in ALS.
FTD neuroinflammation is characterized by [14]:
TDP-43 and tau pathology: Both FTD subtypes feature protein aggregates that trigger inflammation.
Progranulin deficiency: GRN mutations causing FTD lead to progranulin loss, affecting microglial function.
TREM2 variants: TREM2 risk variants increase FTD risk, similar to AD.
Immune gene associations: GWAS studies have identified immune-related genes as FTD risk factors.
HD shows early and progressive neuroinflammation [15]:
Mutant huntingtin effects: Directly affects microglia and astrocytes:
Cytokine elevations: Elevated TNF-α, IL-6, and IL-1β in HD patients and models.
Therapeutic targeting: Reducing neuroinflammation improves outcomes in HD models.
Multiple anti-inflammatory strategies have been tested [16]:
Minocycline: Antibiotic with anti-inflammatory properties. Showed promise in ALS models but failed in clinical trials.
NSAIDs: Epidemiological studies suggested reduced AD risk with chronic NSAID use, but clinical trials failed to demonstrate benefit.
TREM2 agonists: TREM2-activating antibodies are in development for AD.
NLRP3 inhibitors: Small molecule inhibitors are being developed for multiple conditions.
Microglial modulation: Targeting specific microglial pathways rather than broad suppression.
Astrocyte reprogramming: Converting pathogenic A1 astrocytes to protective A2 phenotype.
Peripheral immune modulation: Modulating peripheral immune cell entry into the CNS.
Gene therapy: Delivering anti-inflammatory genes or silencing pro-inflammatory genes.
Neuroinflammation can be assessed through various biomarkers [17]:
PET imaging: TSPO PET ligands visualize microglial activation in vivo.
MRI: Advanced techniques including DTI and MRS can detect inflammation-related changes.
Cytokines: TNF-α, IL-1β, IL-6 levels in CSF and blood.
Soluble receptors: sTREM2, sCD14 reflect microglial activation.
Neurofilament light chain (NfL): Marker of neuronal injury secondary to inflammation.
The blood-brain barrier (BBB) plays a critical role in neuroinflammation [18]:
BBB breakdown: In neurodegenerative diseases, BBB disruption allows peripheral immune cell infiltration. Post-mortem studies show BBB leakage in AD, PD, and ALS brains.
Chemokine gradients: Chemokines released by activated microglia create gradients that attract peripheral immune cells. CCL2 (MCP-1) is particularly important in recruiting monocytes.
Endothelial activation: Activated endothelial cells express adhesion molecules (VCAM-1, ICAM-1) that facilitate leukocyte transmigration.
Therapeutic implications: Restoring BBB integrity may reduce neuroinflammation in neurodegeneration.
TNF-α: One of the most elevated cytokines in neurodegenerative diseases:
IL-10: Counter-regulatory cytokine:
Chemokines are small cytokines that direct immune cell migration [19]:
CCL2/MCP-1: Monocyte chemoattractant:
The complement system is heavily involved in neuroinflammation [20]:
Complement activation: Three pathways converge on C3 activation:
TLRs recognize pathogen-associated and damage-associated molecular patterns [21]:
TLR2 and TLR4: Key pattern recognition receptors:
Beyond TLRs, other PRRs contribute to neuroinflammation [22]:
NOD-like receptors (NLRs): Cytosolic sensors:
Oxidative stress and neuroinflammation are closely linked [23]:
ROS production: Activated microglia produce ROS through NADPH oxidase:
Synaptic loss is the best correlate of cognitive impairment [24]:
Microglial synaptic pruning: Normally eliminates excess synapses:
A bidirectional relationship exists between inflammation and aggregation [25]:
Inflammation promotes aggregation:
Women have higher AD risk but lower PD risk [26]:
Estrogen effects: Anti-inflammatory effects of estrogen:
Aging is the primary risk factor for neurodegeneration [27]:
Inflammaging: Age-related chronic inflammation:
Circadian disruption is common in neurodegeneration [28]:
Clock genes: Regulate inflammatory responses:
GWAS has identified immune-related genetic risk factors [29]:
AD risk genes: Many AD risk genes are immune-related:
Different models capture different aspects [30]:
Toxin models: MPTP (PD), kainic acid (seizures)
Genetic models: APP/PSEN1 (AD), α-synuclein (PD), SOD1 (ALS)
Inflammatory models: LPS injection, viral triggers
Translating findings to humans presents challenges [31]:
Species differences: Human and mouse microglia differ significantly
Model limitations: Cell culture and animal models may not capture human disease
Biomarker development: Need better biomarkers for neuroinflammation
TREM2 on microglia is a major therapeutic target [32]:
Agonists: TREM2-activating antibodies promote microglial clustering around plaques
Antagonists: Blocking TREM2 may reduce harmful inflammation
Gene therapy: Delivering functional TREM2
Colony-stimulating factor 1 receptor regulates microglial survival [33]:
Antagonists: Deplete microglia; controversial effects
Agonists: Promote beneficial microglial phenotypes
Direct inflammasome inhibition shows promise [34]:
Small molecule inhibitors: MCC950, dapansutrile
Targeted delivery: Brain-penetrant compounds needed
Viral delivery of anti-inflammatory genes [35]:
IL-10 delivery: Anti-inflammatory cytokine
TGF-β delivery: Regulatory effects
RNAi targeting: Knock down pro-inflammatory genes
The gut-brain axis influences neuroinflammation [36]:
Gut microbiota effects: Modulate microglial development and function
SCFAs: Short-chain fatty acids from gut bacteria have anti-inflammatory effects
PD gut hypothesis: Gut inflammation may initiate α-synuclein pathology
Metabolism and immunity are intertwined [37]:
Obesity: Increases neuroinflammation; risk factor for AD
Diabetes: Hyperglycemia enhances inflammation
Ketogenic diet: May reduce neuroinflammation
Fasting: Promotes anti-inflammatory responses
Measuring neuroinflammation in clinical trials is essential [38]:
Imaging biomarkers: TSPO PET allows visualization of microglial activation in living subjects. Eleventh-hour studies show increased TSPO binding in AD, PD, and ALS brains.
Fluid biomarkers: CSF and blood measurements of cytokines, chemokines, and glial markers. YKL-40 (chitinase-3-like protein 1) reflects glial activation. Neurofilament light chain (NfL) indicates neuronal injury secondary to inflammation.
Outcome measures: Clinical trials increasingly include inflammatory biomarkers as secondary endpoints. Reduction in inflammatory markers may predict clinical benefit.
Multiple clinical trials are evaluating therapeutic approaches to modulate neuroinflammation across neurodegenerative diseases.
TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a receptor on microglia that regulates phagocytosis and inflammatory responses. TREM2 variants are major genetic risk factors for AD, making it a prime therapeutic target [40].
Mechanism: TREM2 agonists promote microglial clustering around amyloid plaques, enhancing Aβ clearance while potentially reducing harmful inflammation. TREM2 activation shifts microglia toward a protective phenotype.
Key Trials:
The NLRP3 inflammasome is activated by protein aggregates (Aβ, α-synuclein, TDP-43, mutant huntingtin) and drives production of pro-inflammatory cytokines IL-1β and IL-18 [41].
Mechanism: Small molecule inhibitors block NLRP3 assembly or activation, reducing downstream cytokine production. The most advanced inhibitor, MCC950 (also known as CRID3), showed promise in preclinical models.
Key Trials:
Leucine-rich repeat kinase 2 (LRRK2) is highly expressed in microglia and regulates immune cell function. LRRK2 variants are major genetic risk factors for PD, and LRRK2 inhibitors may reduce neuroinflammation in PD [42].
Mechanism: LRRK2 inhibitors reduce microglial activation and pro-inflammatory cytokine production. They may also protect dopaminergic neurons through non-inflammatory mechanisms.
Key Trials:
The complement system is heavily involved in neuroinflammation and synaptic loss in neurodegeneration [43]. C1q, C3, and C5 are key targets.
Mechanism: Complement inhibitors block microglial-mediated synapse elimination (C1q, C3) and reduce inflammatory signaling (C5a).
Key Trials:
CSF1R modulators: Colony-stimulating factor 1 receptor regulates microglial survival and function. CSF1R antagonists can deplete microglia, while agonists may promote beneficial phenotypes.
CD20 antibodies: Rituximab and obinutuzumab target B cells that may contribute to neuroinflammation. Tested in various neurodegenerative conditions.
TNF-α inhibitors: Etanercept, infliximab, and adalimumab have been tested in AD and PD with mixed results.
Minocycline: Antibiotic with anti-inflammatory properties showed promise in ALS models but failed in clinical trials.
Astaxanthin and natural compounds: Various anti-inflammatory supplements in early-stage trials.
| Therapeutic Class | Disease Focus | Development Stage | Key Players |
|-------------------|---------------|-------------------|-------------|
| TREM2 agonists | AD | Phase 1-2 | Roche, Eli Lilly, AC-Immune |
| NLRP3 inhibitors | AD, PD, ALS | Phase 1-2 | Olatec, various |
| LRRK2 inhibitors | PD | Phase 2 | Denali/Biogen, AbbVie, GSK |
| Complement inhibitors | ALS, AD | Phase 2-3 | Alexion, Apellis, various |
| Anti-cytokine therapies | Multiple | Phase 2-3 | Various |
The neuroinflammation therapeutic landscape is rapidly evolving, with multiple mechanisms being tested across different diseases. Success in any one area could validate the broader neuroinflammation hypothesis and accelerate development across all neurodegenerative conditions.
Research directions for the coming decade include [39]:
Single-cell approaches: Single-cell RNA sequencing will further define microglial and astrocyte subpopulations. Understanding heterogeneity may enable precise targeting.
Spatial transcriptomics: Location-specific gene expression will reveal spatial relationships between protein aggregates, immune cells, and neurons.
Human microglia models: Induced pluripotent stem cell-derived microglia may better model human disease.
Precision medicine: Matching therapy to individual inflammatory profiles may improve outcomes.
Neuroinflammation represents a common pathological thread connecting all major neurodegenerative diseases. While disease-specific protein aggregates trigger unique inflammatory responses, common pathways including NF-κB, NLRP3 inflammasome, and microglial activation drive progression across conditions. Understanding these shared mechanisms offers the possibility of developing therapies that could benefit multiple neurodegenerative conditions. Future research should focus on developing targeted anti-inflammatory approaches that modulate specific aspects of neuroinflammation while preserving essential immune functions.
The field of neuroinflammation in neurodegeneration has made remarkable progress. We now understand that chronic activation of brain immune cells is not merely a consequence of neuronal injury but an active driver of pathology. The recognition that protein aggregates themselves serve as danger signals that trigger inflammation has shifted therapeutic paradigms. Importantly, neuroinflammation is not a monolithic process but encompasses diverse microglial and astrocyte activation states with distinct functional consequences. This complexity suggests that successful therapies will need to be precisely targeted rather than broadly immunosuppressive.
Neuroinflammation represents a common pathological thread connecting all major neurodegenerative diseases. While disease-specific protein aggregates trigger unique inflammatory responses, common pathways including NF-κB, NLRP3 inflammasome, and microglial activation drive progression across conditions. Understanding these shared mechanisms offers the possibility of developing therapies that could benefit multiple neurodegenerative conditions. Future research should focus on developing targeted anti-inflammatory approaches that modulate specific aspects of neuroinflammation while preserving essential immune functions.